Please assess the completion status of the following clinical trial:

Trial Title: Spironolactone Plus Metformin in Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight/obese patients with PCOS~Exclusion Criteria:~* Other causes of hyperandrogenism and~* Use of drugs including:~  * oral contraceptive~ * anti-hypertensive agents~ * anti-diabetic drugs~ * agents for weight loss

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: ACTIVE_COMPARATOR): 850 mg/day twice a day
- Metformin plus spironolactone (Type: ACTIVE_COMPARATOR): Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day

Based on this trial design, predict the completion outcome and termination type (if applicable).